PAUL P. CARBONE, M.D.
This content is PDF only. Please click on the PDF icon to access.
Mammary tumors are subject to growth regulation by endocrine factors. Hormone deprivation results in clinical regression of recurrent advanced breast cancer, but somewhat less than 30% of patients benefit from ablative or additive hormone therapy. Recently reported data have indicated that hormone dependence may be predicted by the use of estrogen receptor measurements. The estrogen responsive tumors have a cytoplasmic receptor that binds steroid hormone in vitro. Measurements can be made in vitro by various methods using labeled estrogens and a specific inhibitor. Approximately 60% of specimens from patients with breast cancers have the receptor demonstrable. The older the patient,
CARBONE PP. Antiestrogens and Breast Cancer Treatment. Ann Intern Med. ;83:730–731. doi: 10.7326/0003-4819-83-5-730
Download citation file:
Published: Ann Intern Med. 1975;83(5):730-731.
Breast Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use